evaluate the digital health company amwell on wegovy / semaglutide A big win for Wegovy: Weight loss drug first in history to gain FDA approval for reducing heart risks Novo Nordisk receives FDA approval

Pardis Poorzand an Internal Medicine physician with over ten years of experience helping patients understand, prevent, and treat complex chronic conditions like obesity, high blood pressure, high cholesterol, and diabetes

The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis

Together these adaptogens improve immunity and inflammation, aid hormonal balance, and prolong anti-aging effects

Discuss the potential benefits and risks

Contact us to make an appointment for your initial evaluation

Previously approved only as an intravenous starting dosage, with the option for transitioning to intravenous or subcutaneous maintenance dosage after 18 months of treatment, this approval marks the first time patients can begin treatment with home administration by themselves or their caregiver